INS and type 2 diabetes mellitus: On the other hand, the removal of the p16Ink4a-expressing senescent cells either genetically (using the INK-ATTAC model) or pharmacologically (ABT-263, a Bcl-2 inhibitor) restored glucose tolerance and insulin sensitivity in the type 2 diabetes model [64].